Search Results

Background: Lung cancer is the leading cause of death in the United States. We are challenged with finding the optimal treatment for patient subgroups in a real-world setting. Treatment options have expanded to include immunotherapies versus platinum-based therapies to improve the quality of cancer care. Platinum combinations are known to have overall response rates of 25%–35%, time to progression of 4–6 months, and a median survival of 8–10 months. The purpose of this study was to determine how long metastatic NSCLC patients were on first-line treatments and what characteristics potentially contribute to the duration of therapy prior to progression. Methods: All patients with a diagnosis of metastatic NSCLC that received first line treatment between January 1, 2016 and December 31, 2017 but later switched to a different treatment because of disease progression or intolerance were included in the study (n=1,222). The sample, obtained from a nationwide database of treatment requests, was stratified into 4 groups based on the type of treatment the patient received: single agent (n=66), PD-1/PDL-1 (n=157), platinum doublet (n=720), and platinum triplet (n=279). Chi-square and Kruskal-Wallis tests were performed as appropriate. Results: The findings suggested that the median duration to progression was shorter for single agents as compared to multiple agent treatments (Χ ² =7.67, P=.05). The median treatment duration for the groups were as follows: 90 days for single agent, 90 days for PD-1/PDL-1, 93 days for platinum doublet, and 111 days for platinum triplet. Additional analyses were conducted to understand whether pathway adherence and growth factor usage impact the duration of time to discontinuation within each group. Conclusions: These data provide insight into the duration of first line treatments for advanced lung cancer. Shorter duration times were found for single agent treatments as compared to multiple agent treatments.

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer address all aspects of management for breast cancer. The treatment landscape of metastatic breast cancer is evolving constantly. The therapeutic strategy takes into consideration tumor biology, biomarkers, and other clinical factors. Due to the growing number of treatment options, if one option fails, there is usually another line of therapy available, providing meaningful improvements in survival. This NCCN Guidelines Insights report focuses on recent updates specific to systemic therapy recommendations for patients with stage IV (M1) disease.

Several new systemic therapy options have become available for patients with metastatic breast cancer, which have led to improvements in survival. In addition to patient and clinical factors, the treatment selection primarily depends on the tumor biology (hormone-receptor status and HER2-status). The NCCN Guidelines specific to the workup and treatment of patients with recurrent/stage IV breast cancer are discussed in this article.

These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy for women with hormone receptor–positive, HER2-negative early-stage invasive breast cancer. This report summarizes these updates and discusses the rationale behind them.

The NCCN Guidelines for Breast Cancer include up-to-date guidelines for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory breast cancer, male breast cancer, and breast cancer during pregnancy. These guidelines are developed by a multidisciplinary panel of representatives from NCCN Member Institutions with breast cancer–focused expertise in the fields of medical oncology, surgical oncology, radiation oncology, pathology, reconstructive surgery, and patient advocacy. These NCCN Guidelines Insights focus on the most recent updates to recommendations for adjuvant systemic therapy in patients with nonmetastatic, early-stage, hormone receptor–positive, HER2-negative breast cancer.

The therapeutic options for patients with noninvasive or invasive breast cancer are complex and varied. These NCCN Clinical Practice Guidelines for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory breast cancer, and management of breast cancer during pregnancy. The content featured in this issue focuses on the recommendations for overall management of ductal carcinoma in situ and the workup and locoregional management of early stage invasive breast cancer. For the full version of the NCCN Guidelines for Breast Cancer, visit NCCN.org.

Breast cancer is treated with a multidisciplinary approach involving surgical oncology, radiation oncology, and medical oncology. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget’s disease, Phyllodes tumor, inflammatory breast cancer, and management of breast cancer during pregnancy. The content featured in this issue focuses on the recommendations for overall management of systemic therapy (preoperative and adjuvant) options for nonmetastatic breast cancer. For the full version of the NCCN Guidelines for Breast Cancer, visit NCCN.org.